| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Tissue factor;TF;Coagulation factor III;Thromboplastin;CD142;F3; |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Form | Liquid |
| Host | |
| Immunogen | A synthesized peptide derived from human CYP24A1 |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Storage | |
| Target | |
| UniProt # |
Overview
This product is an anti-CYP24A1 antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone 20C68; isotype IgG; reactivity: Human. Reported application contexts include WB (as provided in the source record). Boster Bio Anti-CYP24A1 Rabbit Monoclonal Antibody catalog # M00343. Tested in WB application. This antibody reacts with Human.
Key elements and design rationale
- Target: CYP24A1 (Tissue factor).
- Antibody format: Monoclonal; clone 20C68; isotype IgG.
- Host: Rabbit.
- Species reactivity: Human (confirm in your model system with appropriate controls).
This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.
Biological background
CYP24A1 (protein: P2X purinoceptor 1) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Initiates blood coagulation by forming a complex with circulating factor VII or VIIa. The [TF:VIIa] complex activates factors IX or X by specific limited protolysis. TF plays a role in normal hemostasis by initiating the cell-surface assembly and propagation of the coagulation protease cascade. . Reported cellular localization context: Isoform 1: Membrane; Single-pass type I membrane protein. Tissue expression notes (as provided): Lung, placenta and pancreas. .
Research relevance and current trends
- Research context keywords from the source record include: Cardiovascular.
- Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
- Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.
Common research applications
- Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.
Workflow ideas (metafield): Validate CYP24A1 antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect CYP24A1 expression by Western blot in cell or tissue lysates, Compare relative CYP24A1 levels across experimental conditions (dose/time-course) using antibody-based readouts
Notes for experimental interpretation
- Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
- Apparent molecular weight may vary by sample type and processing (observed MW: 35 kDa; calculated MW: 33068 MW).
- Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.
Additional product details (from the source record)
- Molecular weight (observed): 35 kDa
- Cellular localization (provided): Isoform 1: Membrane; Single-pass type I membrane protein.
- Tissue details (provided): Lung, placenta and pancreas. .
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
